Hansa Biopharma AB (publ) (STO:HNSA)
34.48
+2.24 (6.95%)
Jun 12, 2026, 5:29 PM CET
Hansa Biopharma AB Employees
Hansa Biopharma AB had 122 employees as of March 31, 2026. The number of employees decreased by 16 or -11.59% compared to the same quarter last year.
Employees
122
Change
-16
Growth
-11.59%
Revenue / Employee
1.56M SEK
Profits / Employee
-5.67M SEK
Market Cap
3.51B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 122 | -16 | -11.59% |
| Dec 31, 2025 | 125 | -10 | -7.41% |
| Sep 30, 2025 | 133 | -2 | -1.48% |
| Jun 30, 2025 | 140 | -6 | -4.11% |
| Mar 31, 2025 | 138 | -28 | -16.87% |
| Dec 31, 2024 | 135 | -33 | -19.64% |
| Sep 30, 2024 | 135 | -33 | -19.64% |
| Jun 30, 2024 | 146 | -16 | -9.88% |
| Mar 31, 2024 | 166 | 7 | 4.40% |
| Dec 31, 2023 | 168 | 18 | 12.00% |
| Sep 30, 2023 | 168 | 23 | 15.86% |
| Jun 30, 2023 | 162 | 17 | 11.72% |
| Mar 31, 2023 | 159 | 18 | 12.77% |
| Dec 31, 2022 | 150 | 19 | 14.50% |
| Sep 30, 2022 | 145 | 18 | 14.17% |
| Jun 30, 2022 | 145 | 32 | 28.32% |
| Mar 31, 2022 | 141 | 40 | 39.60% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioInvent International AB | 112 |
| Oncopeptides AB | 75 |
| Egetis Therapeutics AB | 44 |
| Saniona AB | 43 |
| Vicore Pharma Holding AB | 37 |
| Genovis AB (publ.) | 36 |
| Flerie AB | 8 |
| SynAct Pharma AB | 8 |
Hansa Biopharma AB News
- 9 days ago - Hansa Biopharma AB Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 17 days ago - Hansa Biopharma AB Conference Call Transcript - GuruFocus
- 17 days ago - Hansa Biopharma AB Transcript: Study result - Transcripts
- 17 days ago - Hansa Biopharma AB Press release: Study result - Filings
- 17 days ago - Hansa Biopharma AB Slides: Study result - Filings
- 18 days ago - Hansa Biopharma AB: Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation - Finanz Nachrichten
- 18 days ago - Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation - PRNewsWire
- 19 days ago - Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 - PRNewsWire